Key facts
- This page summarizes Jane E. Kiernan's Form 4 filing for Axonics, Inc..
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 15 Nov 2024, 09:00.
Jane E. Kiernan - 15 Nov 2024 Form 4 Insider Report for Axonics, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 15 Nov 2024
- Net transaction value
- -$1,410,131
- SEC form
- 4
- Accepted by SEC
- 15 Nov 2024, 09:00:20 UTC
- Prior SEC filing
- 22 May 2024
- Next SEC filing
- 21 May 2025
- Source filing
- View source filing
- Reporting owner signature
- Kari L. Keese, as Attorney-in-fact for Jane E Kiernan
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jane E. Kiernan filed Form 4 for Axonics, Inc. on 15 Nov 2024.
Change
- Previous filing in this sequence was filed on 22 May 2024.
- Current net transaction value: -$1,410,131.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AXNX
transaction
Common Stock
Disposed to Issuer
- Transaction value
- $1,410,131
- Shares
- -19,861
- Change %
- -100%
- Price
- $71.00
- Shares after
- 0
- Date
- 15 Nov 2024
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Reflects the disposition of the reporting person's shares of the Issuer's common stock, upon the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 8, 2024 (the "Merger Agreement"), among the Issuer, Boston Scientific Corporation ("Parent") and Sadie Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger of Merger Sub with and into the Issuer with the Issuer as the surviving corporation (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective time"), each outstanding share of the Issuer's common stock was canceled and converted automatically into the right to receive $71.00 in cash, without interest (The "Merger Consideration").